Landscapes / Companies

Novartis

Public NVS · Switzerland

FollowEvery new trial, moved date and filing, and a Monday email
Furthest along
31 approved
1 filed
Next date
inclisiran, Phase 4 trial completes
Drugs
101
in active trials · 279 in all
Trials
247 active
940 since 2021

Drugs101

DrugHow it worksPartnerStageNext dateDetails
Small interfering RNA
Approved 27 Nov 2026soonPhase 4 trial completes
AAA617not checked
—
On the market 23 Dec 2026Phase 2 trial completes
Complement factor B inhibitor
Approved 30 Dec 2026Phase 2 trial completes
Alpelisibnot checked
PI3K inhibitor
Approved 28 Jan 2027Phase 3 trial completes
Kinase inhibitor
Approved 1 Feb 2027Phase 2 trial completes
Tyrosine kinase inhibitor
Approved 2 Feb 2027Phase 2 trial completes
BTK inhibitor
Approved 22 Feb 2027Phase 3 trial completes
Kinase Inhibitor; mTOR inhibitor immunosuppressant
Approved 26 Feb 2027Phase 3 trial completes
Cell therapy
Approved 31 Mar 2027Phase 3 trial completes
Ofatumumabnot checked
CD20-directed cytolytic antibody
Approved 13 Apr 2027Phase 4 trial completes
Ruxolitinibnot checked
Kinase Inhibitor; janus kinase inhibitor
Incyte
Approved 30 Apr 2027Phase 3 trial completes
Kinase inhibitor
Approved 9 Jun 2027Phase 4 trial completes
Cortisol synthesis inhibitor
Recordati
Approved 21 Jul 2027Phase 2 trial completes
Kinase inhibitor
Approved 30 Jul 2027Phase 2 trial completes
Asciminibnot checked
—
Approved 3 Sep 2027Phase 1/2 trial completes
—
Approved in the EU 1 Feb 2028Phase 3 trial completes
Secukinumabnot checked
Monoclonal antibody
Approved 8 Feb 2028Phase 4 trial completes
—
Approved 7 Mar 2028Phase 1/2 trial completes
—
Approved 7 Mar 2028Phase 1/2 trial completes
Endothelin receptor antagonist
Approved 14 Apr 2028Phase 3 trial completes

See all 101 drugs

Sign in free to see the whole list. No card, no password.

Sign in free

SEC filings

All on SEC.gov

No filings loaded yet.

About

No active trial
178 other drugs
Registry names
5 names in ClinicalTrials.gov
Sources
ClinicalTrials.gov updated 18 Nov 2026 · SEC filings Industry-sponsored drug trials since 2021

Follow Novartis

Following is part of Solo: you see every change to Novartis the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in